IE stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
Company Logo

Endo International plc

ENDPNASDAQ

0.29

USD
- -
(- -)
Market Closed
-0.09P/E
- -Forward P/E
-0.00P/E to S&P500
- -MMarket CAP
- -Div Yield
Upcoming Earnings
- -
Shares Short
Short % of Float
- -
Short % of Shares Outs.
- -
% Held by Insiders
- -
% Held by Institutions
- -
Beta
1.15
PEG Ratio
- -
52w. high/low
- -/- -
Avg. Daily Volume
62.33M
Return %
Stock
S&P 500
1 year
(94.84)
(13.40)
3 years
(96.23)
31.74
5 years
(98.70)
59.24
Scale: |
High
Low
35.85
26.04
28.48
13.87
26.14
15.75
38.20
19.19
44.53
26.02
39.29
25.49
67.63
25.01
82.16
53.62
96.58
46.66
61.14
12.56
17.99
5.77
18.50
5.27
12.49
1.97
7.31
2.08
10.89
1.94
3.98
0.09
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
6.83
8.11
10.23
12.48
14.79
23.30
27.32
22.69
18.69
14.72
18.01
15.54
13.16
12.89
12.66
12.86
12.53
Earnings per share
1.03
1.70
2.12
2.28
2.23
1.60
(6.68)
(5.94)
(4.69)
(6.73)
(15.03)
(9.12)
(4.61)
(1.87)
0.80
(2.44)
(3.12)
FCF per share
2.25
2.58
2.75
2.42
3.74
5.49
5.67
1.65
1.64
(0.29)
1.65
1.92
0.81
0.15
(1.41)
1.43
1.11
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.35
0.15
0.14
0.11
0.17
0.51
0.95
0.94
0.56
0.57
0.71
0.56
0.39
0.28
3.15
0.33
0.47
Book Value per sh.
7.82
9.65
9.15
12.79
15.01
16.88
9.68
4.56
15.43
26.87
12.13
2.17
(2.22)
(3.83)
(2.83)
(5.34)
(4.13)
Comm.Shares outs.
133
134
123
117
116
117
111
115
154
222
223
223
224
226
229
233
234
Avg. annual P/E ratio
29.4
18.1
11.0
8.9
11.9
22.1
(4.9)
(6.8)
(14.6)
(11.3)
(1.8)
(1.2)
(2.2)
(3.2)
5.5
(2.3)
(0.1)
P/E to S&P500
1.6
1.0
0.5
0.1
0.6
1.4
(0.3)
(0.4)
(0.8)
(0.6)
(0.1)
(0.0)
(0.1)
(0.1)
0.1
(0.1)
(0.0)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
910
1,086
1,261
1,461
1,716
2,730
3,027
2,617
2,877
3,269
4,010
3,469
2,947
2,914
2,903
2,993
2,928
Operating margin
23.1%
29.2%
30.7%
26.7%
27.1%
18.6%
(18.2)%
(16.3)%
(31.2)%
(28.6)%
(86.6)%
(27.7)%
(15.9)%
20.0%
20.8%
25.5%
23.1%
Depreciation (m)
18
16
50
100
108
237
286
256
332
633
983
984
724
613
519
457
445
Net profit (m)
138
227
262
266
259
188
(740)
(685)
(721)
(1,495)
(3,347)
(2,035)
(1,031)
(423)
184
(569)
(721)
Income tax rate
41.0%
35.6%
34.9%
25.9%
31.8%
31.2%
7.2%
4.3%
35.7%
79.1%
17.8%
16.9%
(2.4)%
(4.5)%
1,033.2%
(4.1)%
302.4%
Net profit margin
15.2%
21.0%
20.8%
18.2%
15.1%
6.9%
(24.5)%
(26.2)%
(25.1)%
(45.7)%
(83.5)%
(58.7)%
(35.0)%
(14.5)%
6.3%
(19.0)%
(23.4)%
Working capital (m)
698
668
797
808
624
666
241
1,158
208
1
(45)
50
393
1,126
1,159
1,085
1,117
Long-term debt (m)
- -
- -
372
323
1,046
3,424
3,038
3,324
4,202
8,252
8,141
8,242
8,224
8,360
8,281
8,049
8,073
Equity (m)
1,041
1,292
1,128
1,497
1,742
1,978
1,073
526
2,375
5,968
2,702
485
(498)
(867)
(648)
(1,244)
(1,311)
ROIC
13.0%
17.4%
17.0%
14.6%
9.7%
5.0%
(11.9)%
(10.6)%
(7.4)%
(3.0)%
(25.3)%
(15.8)%
(5.9)%
2.0%
(52.1)%
0.3%
4.0%
Return on capital
16.7%
20.8%
21.0%
16.0%
11.4%
6.2%
(9.4)%
(8.2)%
(8.2)%
(11.6)%
(25.2)%
(15.4)%
(4.7)%
1.6%
4.8%
0.2%
(1.6)%
Return on equity
13.2%
17.6%
23.2%
17.8%
14.9%
9.5%
(69.0)%
(130.3)%
(30.4)%
(25.1)%
(123.9)%
(419.8)%
207.0%
48.8%
(28.4)%
45.7%
55.0%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
(2.8)%
(2.2)%
109.7%
- -
13.6%
5.4%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
6 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 9,758
Total assets
$ 8,447
Long-term debt
$ 8,073
Cash and equiv.
$ 1,413
Goodwill
$ 3,197
Retained earnings
$ (10,053)
Common stock
234
Enterprise Value
$ - -
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,455
1,213
1,507
Receivables
516
575
- -
Inventory
328
352
284
Other
288
31
977
Current assets
2,586
2,413
2,715
Acc. Payable
102
94
- -
Debt due
45
46
33
Other
1,314
1,114
1,597
Current liabilities
1,460
1,254
1,630
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
3.10%
(3.36)%
0.64%
Cash flow
(202.79)%
(347.33)%
(245.52)%
Earnings
(409.38)%
(165.31)%
(52.39)%
Dividends
- -
- -
- -
Book value
91.99%
(15.52)%
28.10%
Insider Trading
Type
Shares
Date
Tursi James Patrick
Return
280,373
07/15/22
Barry Patrick A
InKind
4,975
03/30/22
Barry Patrick A
Exempt
16,957
03/30/22
Barry Patrick A
Exempt
42,341
03/30/22
Maletta Matthew Joseph
InKind
10,179
03/30/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
820
688
635
760
2,903
2021
718
714
772
789
2,993
2022
652
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.57
0.05
(0.33)
0.52
0.80
2021
0.18
(0.07)
(0.33)
(2.39)
(2.61)
2022
(0.31)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
CEO:
Mr. Blaise Coleman
Full-time employees:
3,103
City:
DUBLIN
Address:
Minerva House, Simmonscourt Road
IPO:
Mar 3, 2014
Website:
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Recent News
· 10 Aug, 2022 · The Wall Street Journal
· 2 Nov, 2021 · The Wall Street Journal